Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy.

Takashi KuniharaHeinrike WilkensMichael HalankMatthias HeldRyota NomuraTakashi IgarashiFumihiro SataHans-Joachim Schäfers

Published in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2021)

Preoperative treatment of CTEPH patients with bosentan for 2-8 months can improve post-PEA PVR without adverse clinical events in patients with a high preoperative PVR. A temporary bridging regime appears beneficial in selected patients prior to PEA.

Keyphrases

pulmonary arterial hypertension
end stage renal disease
patients undergoing
ejection fraction
newly diagnosed
prognostic factors
emergency department
drug induced